Sanofi-Aventis, a pharmaceutical company, has signed a three-year contract to extend the use of Advanced Chemistry Development’s software throughout its R&D sites worldwide. The agreement includes provisions for continuing support, and a special pricing structure beneficial to both companies.
Sanofi-Aventis uses a range of Advanced Chemistry Development’s (ACD/Labs) analytical, predictive, and nomenclature tools such as ACD/SpecManager, ACD/Structure Design Suite, ACD/PhysChem Batch predictors, and ACD/Name.
Additional support provided under the new agreement will encourage greater adoption of these tools within all R&D sites, in particular in Europe and the USA. The new contract provides a special pricing model for the company based on the level of deployment throughout the various sites.
Advanced Chemistry Development, headquartered in Toronto, Canada, creates software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, chromatographic separation, medicinal chemistry, systematic nomenclature generation, chemical patenting etc.,
Yves Lorrain, director of sales for Chemcad-a distributor of products at ACD/Labs, said: Sanofi-Aventis has been using ACD/Labs tools in its R&D groups throughout the organization for more than five years.
With this contract we will continue to provide the same high level of support and allow Sanofi-Aventis R&D scientists to maximize the intrinsic value of each of the ACD/Labs modules they use.